Valproate unbound fraction and distribution volume following rapid infusions in patients with epilepsy.
The availability of an intravenous formulation now makes possible rapid administration of valproate (VPA) loading doses, but estimates of key VPA pharmacokinetic parameters in patients have limited the use of this approach. VPA disposition was characterized in 112 epilepsy patients, with or without enzyme inducing comedications, randomized to either 3.0 or 1.5mg/kg/min infusions of valproate sodium injection. Maximum dose was </=15mg/kg per infusion. Total and unbound plasma VPA concentrations were determined from blood samples obtained prior to and for 6h following the infusion. Analyses of covariance assessed the effect of induction, weight, age, gender, albumin, creatinine, and infusion rate on pharmacokinetics. Maximum total and unbound VPA concentrations were 94 and 14mg/l, respectively. Total concentration fell below 50mg/l within 3h in induced and 6h in uninduced patients. VPA unbound fraction decreased from 15% at maximum concentration to 9% at 45mg/l. The mean (S.D.) distribution volume was 0.21 (0.044)l/kg. Induction status, albumin concentration, and infusion rate significantly affected pharmacokinetics. Measurement of unbound VPA may be useful when alterations in binding are suspected. Infusions up to 3mg/kg/min produce predictable total VPA concentrations when induction status and albumin levels are considered.
Cloyd
James C
JC
College of Pharmacy, University of Minnesota, Minneapolis, MN, USA.
Dutta
Sandeep
S
Cao
Guoliang
G
Walch
Julia K
JK
Collins
Stephen D
SD
Granneman
G Richard
GR
D000293:Adolescent; D000328:Adult; D000368:Aged; D000465:Algorithms; D000927:Anticonvulsants / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D004827:Epilepsy / Q000188:drug therapy / Q000378:metabolism*; D005260:Female; D016231:Fluorescence Polarization Immunoassay; D006801:Humans; D007223:Infant; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011485:Protein Binding; D014018:Tissue Distribution; D014635:Valproic Acid / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use
D000927:Anticonvulsants; D014635:Valproic Acid